Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform

Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded Eli Lilly and Company (NYSE:LLY) to Market Perform from Outperform with a $715 price target.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

The rating update came after Eli Lilly and Company (NYSE:LLY) posted its fiscal Q2 2025 earnings the same day, with revenue growing 38% to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.

Eli Lilly and Company (NYSE:LLY) also raised the midpoint of its 2025 full-year revenue guidance by $1.5 billion, taking it to the $60 billion to $62 billion range. It also raised its reported EPS guidance to be in the $20.85 to $22.10 range.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.